CLINICAL STUDY ON SULEACTAM/CEFOPERAZONE IN PULMONARY AND RESPIRATORY INFECTIONS COMBINED WITH CHRONIC RESPIRATORY DISEASE
1984 Volume 32 Issue Supplement4 Pages 341-346
Details
1984 Volume 32 Issue Supplement4 Pages 341-346
Sulbactam, a new β-Jactamase inhibitor and cefoperazone combination (SBT/CPZ) was administered to 20 cases of RTI patients. SBT/CPZ was administered 1-4g twice a day by drip infusion for 5-47 days. Clinical efficacy was excellent in 4, good in 7, poor in 5, and no response in 4 patients, and overall clinical efficacy rate was 55%. Causative organisms were isolated in 15 patients out of 20 patients. Bacteriological effects were obtained in 8 patients. Diarrhea and nausea were noted in each one patient and elevation of Al-P was noted in 2 patients.
